创新药物医保落地，助力慢淋治疗加速迈进“无化疗时代”

Core Insights - Chronic lymphocytic leukemia (CLL) is a prevalent B-cell malignancy primarily affecting the elderly, with a median onset age of 65 in China, and its incidence is rising due to an aging population and improved diagnostic capabilities [1] - The emergence of targeted therapies, particularly the BTK inhibitor Acalbrutinib, is revolutionizing the treatment landscape for CLL, marking a shift towards a "chemotherapy-free era" [1] Group 1: Acalbrutinib's Impact - Acalbrutinib has achieved rapid insurance coverage for first-line treatment of CLL/SLL, facilitating greater accessibility for patients [3] - The drug's core advantages include significant survival benefits and the ability to achieve deeper treatment goals, such as "deep remission," which is crucial for long-term disease control [4] - In a phase III registration study involving 192 newly diagnosed CLL patients, a complete response (CR) rate of 12.1% was observed, with low incidences of cardiovascular events, bleeding, infections, diarrhea, and rashes [5] Group 2: Ongoing Research and Future Directions - Acalbrutinib has previously been included in insurance coverage for multiple lymphoma-related indications, expanding its clinical applicability [6] - A large-scale, multi-center real-world study (OBaC study) is underway to evaluate the efficacy and safety of Acalbrutinib in newly diagnosed CLL patients, with plans to enroll 400 patients across 27 centers by the end of 2027 [6]